Invivyd Inc. logo

Invivyd Inc.(IVVD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$0.58
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IVVD

11/13/2026: IVVD (2-star) is currently NOT-A-BUY. Pass it for now.

Invivyd Inc. is a commercial-stage biopharmaceutical stock focused on discovering and developing monoclonal antibody therapies for serious viral infectious diseases like COVID-19. The company's main operational strength is its commercialized product PEMGARDA, which provides growing product revenue targeting vulnerable immunocompromised populations. Its primary growth catalyst centers on advancing next-generation candidates like VYD2311 and expanding its pipeline into other viral targets. However, the company faces substantial risks, including ongoing net losses, cash burn, regulatory uncertainties, and fierce competition from major vaccine makers. Invivyd best suits high-risk growth investors willing to monitor clinical data readouts, regulatory milestones, and balance sheet cash runways.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers expanding product revenues and clinical pipeline catalysts, balanced by execution risks.
Momentum investorStrong fit while signal remains positiveShort-term trading swings often respond to clinical trial readouts and regulatory updates.
Value investorWeak fitThe company is currently unprofitable with negative earnings and ongoing cash burn.
Dividend investorWeak fitInvivyd pays no dividends and reinvests all capital into research and operations.
Low-risk investorWeak fitSmall-cap biotechnology stocks face high clinical, regulatory, and price volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stock prices swing sharply based on clinical trial results and regulatory decisions.
Valuation riskMedium / highValuation relies heavily on future commercial adoption rather than current net profitability.
Competition risk (infectious disease and vaccine developers)HighAlternative treatments and dominant vaccine incumbents constrain market penetration.
Business qualityMediumProprietary discovery platforms provide long-term promise, though commercial scale is still developing.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends on clinical trial outcomes, regulatory approvals, and commercial adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 171.58M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 4.2M shares
Beta 1.29
52 Weeks Range 0.53 - 3.07
Updated Date 11/15/2026
52 Weeks Range 0.53 - 3.07
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.33

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 122.1%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IVVD receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
IVVD has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+69.1%) and strong revenue growth (+110.5%) are partially offset by weak cash generation (FCF margin -109.1%), weak profitability (net margin -98.2%).

Financial Health Rating

★★★★★
IVVD's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 77.0%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is IVVD's strongest growth driver at +110.5% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+69.1%, strong) and free-cash-flow growth (+65.8%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 87.5% and approximately 70.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.41% supports management-shareholder alignment.

Top 5 Institutional Investors

Jupiter Topco LLC 11.59%
Bvf Inc 9.56%
Maverick Capital Ltd 6.44%
Perceptive Advisors LLC 6.27%
BlackRock Inc 5.47%

Unit Economics (Per $1K Revenue)

★★★★★
IVVD generates approximately $930 of gross profit, $-1,040 of operating income, and $-1,091 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
IVVD has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Sales (PEMGARDA)Commercial sales of pemivibart to healthcare providers and specialty distributors for COVID-19 pre-exposure prophylaxis.The primary engine of current revenue generation, growing quarter-over-quarter.
Grants and CollaborationsFunding from research grants or strategic partnerships supporting specialized drug discovery initiatives.Secondary source of non-dilutive capital supporting early research programs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 6.97
Enterprise Value 19.68M
Price to Sales(TTM) 2.94
Enterprise Value 19.68M
Price to Sales(TTM) 2.94
Enterprise Value to Revenue 0.34
Enterprise Value to EBITDA 0.78
Shares Outstanding 294.76M
Shares Floating 207.83M
Shares Outstanding 294.76M
Shares Floating 207.83M
Percent Insiders 7.41
Percent Institutions 87.53

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.